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Abstract
Background: The purpose of this study is to evaluate the impact of switching from sterile water to 5 % glucose
(G5W) for the administration of yttrium-90 (90Y)-resin microspheres on the total activity of 90Y administered
(expressed as a proportion of the prescribed/calculated activity), as well as the number of cases of stasis and the
reported incidence of discomfort during the selective internal radiation therapy (SIRT) procedure.
Methods: In December 2013, we switched from sterile water to G5W for the administration of SIRT using 90Y resin
microspheres in all patients. This retrospective observational single-center case series describes our experience in
the months preceding and after the switch. Apart from the change in administration medium, the protocol for SIRT
was otherwise identical.
Results: One hundred and four SIRT procedures were performed on 78 patients (45 male, mean age: 63 years,
range: 31–87 years) with either unresectable hepatocellular carcinoma, cholangiocarcinoma, or chemorefractory
liver-dominant metastatic cancer. Compared with sterile water, the whole prescribed activity was administered in
significantly more procedures with G5W: 85 vs. 22 %; p < 0.0001. A significantly higher proportion of the calculated
activity was administered with G5W: 96.1 ± 11.0 % vs. 77.4 ± 24.3 % (p < 0.0001). G5W procedures were also
associated with a significantly lower incidence of stasis (28 vs. 11 % procedures; p = 0.02) and mild-to-moderate
upper abdominal pain during the procedure (1.8 vs. 44 % procedures; p < 0.0001).
Conclusions: Replacing sterile water with isotonic G5W during administration favorably impacts on the safety of
SIRT, eliminates and/or minimizes flow reductions and stasis/reflux during administration of 90Y resin microspheres,
improves percentage activity delivered, and reduces peri-procedural pain.
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Background
Selective internal radiation therapy (SIRT) is a form of
liver-directed brachytherapy whereby microspheres
loaded with yttrium-90 (90Y) serve as sealed sources of
localized beta radiation [1]. The microspheres are deliv-
ered via the tumor-feeding arteries and embed perman-
ently in the pre-capillary arterioles of liver tumors [2].
The goal of SIRT is to deliver potent beta radiation only
to tumor cells via the enhanced arterial blood supply of
the tumor so that there is minimal damage to the sur-
rounding (healthy) liver parenchyma and negligible
microsphere migration to other organs [1, 3]. One vial
of 3 GBq 90Y resin microspheres contains between 40
and 80 million micron-sized microspheres [4]. The resin
microspheres have a specific gravity close to plasma and
so are neutrally buoyant [5] and minimally embolic
(compared with large particles such as those used for
transarterial chemoembolization (TACE)) [6]. The resin
microspheres, as a result of their specific gravity, rely on
sufficient blood flow distal to the catheter tip for their
delivery and distribution to the tumor sites. Equally, the
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localized radiation effect [7] is enhanced because the
oxygen supply to the tumor is maintained, and so, the
primary mechanism of SIRT is internal radiation rather
than vascular embolization causing ischemia [8]. The
physical features of the microspheres are also important
to reduce the risk for stasis of blood flow [9] and the risk
of potential microsphere reflux into the normal paren-
chyma or to the gastrointestinal tract.
Computer modeling of flow dynamics after micro-
sphere release shows that targeted delivery (whether
whole liver, lobar, segmental, or sub-segmental) is deter-
mined by the specific positioning of the microcatheter
and blood flow in the hepatic arterial tree [5, 10]. In the
clinic, catheter-directed therapies such as SIRT are eval-
uated using real-time image guidance using digital sub-
traction angiography (DSA) together with an injectable
liquid non-ionic contrast media (CM) which enable the
interventional radiologist to ensure the correct catheter
position and assessment of vessel behavior, such as
spasm or dissection. The infusion of 90Y resin micro-
spheres under direct fluoroscopic guidance also enables
the visualization of blood flow direction and velocity
around the catheter and so ensures their safe delivery.
A standardized approach for the delivery of 90Y resin
microspheres has evolved worldwide over time with
periodic publication of updated guidance [4, 11]. This
guidance is based on a process of regular review and/or
formalized audit to ensure the optimal outcomes with
this technique. One observed effect of SIRT in some pa-
tients is early stasis in which the delivery of the whole
calculated activity of resin microspheres was halted as a
result of a lack of antegrade flow at angiography during
infusion which is sporadically reported in the literature
[12]. Although stasis can impede delivery of the full pre-
scribed activity of 90Y, two separate published studies have
found that stasis neither affected early response outcomes
as assessed by computed tomographic (CT) at 3 months
post-SIRT [12] nor were there differences in survival when
actual dose administered was either above or below a tar-
get of 80 % of the prescribe dose [13]. Nevertheless, mech-
anisms to improve the delivery of SIRT and reduce the
potential for stasis continue to evolve.
The administration of SIRT using 90Y resin micro-
spheres is normally carried out with sterile water. It has
been hypothesized that the flush of sterile water may
cause a temporary change in the osmolality of the blood
leading to hemolysis [14] and vascular endothelial injury
with subsequent vasospasm and premature stasis [15–17].
In some leading clinics, glucose 5 % water (G5W) in com-
bination with non-ionic contrast medium is currently used
instead of sterile water for the administration of 90Y resin
microspheres because of its approximate isotonicity to
plasma. Although there is anecdotal data from these cen-
ters to suggest that G5W may improve the efficacy and
safety of SIRT by reducing the incidence of stasis and im-
proving the activity of 90Y administered, the experience of
these clinics using G5W is yet to be published.
The decision to suspend 90Y resin microspheres in
G5W was based on unpublished data from Sirtex Medical
Ltd. which examined the compatibility of SIR-Spheres®
microspheres with non-ionic contrast media and fluids
suitable for intravascular use other than sterile water.
These in vitro studies found that G5W (isotonic) had
equivalent compatibility to sterile water (hypotonic) with
similar binding affinity of 90Y to the resin substrate.
In December 2013, we switched from sterile water to
G5W for application of resin microspheres in all pa-
tients. This paper describes our experience with SIRT
(in the months preceding and after the change to G5W)
with respect to the total activity administered (expressed
as a proportion of the calculated activity) and the num-
ber of cases of stasis and flow reduction as well as the




This was a retrospective observational single-center case
series evaluation of 78 patients with liver-dominant dis-
ease of varying primary tumor origins who were treated
consecutively with 90Y resin microspheres (SIR-Spheres®,
Sirtex Medical Limited, North Sydney, Australia) be-
tween January 2013 and November 2014. Most candi-
dates for SIRT had either unresectable hepatocellular
carcinoma (24.4 %) or unresectable liver-predominant
metastases from colorectal cancer (25.6 %) and neuroen-
docrine tumors (21.8 %) or breast cancer (14.1 %)
(Table 1). The decision to perform SIRT was guided in
all cases by the well-defined published criteria for SIRT
[18] as well as interdisciplinary consent after discussion
with the liver tumor board. All patients provided written
informed consent. This study was approved by our local
ethics committee, University of Bonn-faculty of Medicine.
Pretreatment angiography and SIRT
The technique and rationale for the various procedures
involved with delivering radioactive microspheres into
the hepatic artery are well described elsewhere [19–22].
Apart from the change in application agent from sterile
water to G5W for 90Y resin microspheres, the process
for the pretreatment review, angiography, dosimetry and
treatment procedure for SIRT, and the clinical team
were otherwise identical.
All patients underwent preparatory hepatic arteriog-
raphy to define the vascular anatomy of the liver and to
assess the vascularity of hepatic tumors 1–2 weeks prior
to SIRT. This was combined with technetium-99m-
labelled human serum albumin (99mTc-HSA) simulation
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and single-photon emission CT (SPECT) imaging to rule
out any shunting to the lung and to detect non-target
delivery to the gastrointestinal tract, which was cor-
rected, prior to delivery of SIRT. The prescribed activity
was calculated principally using the body surface area
method based on the target volumes of the tumor and
liver for each patient [18].
On the treatment day, 90Y resin microspheres were ad-
ministered after confirming that there were no new col-
lateral vessels connecting to the gastrointestinal tract.
SIRT was performed under constant fluoroscopic guid-
ance; eminent stasis or backflow led to the termination
of treatment irrespective of the amount of activity given
at that time point. Either sterile water or G5W was used
Table 1 Baseline patient and disease characteristics and treatment approach with SIRT according to the number of procedures with
each application agent
Sterile water Isotonic 5 % glucose (G5W) p value*
Gender, n (%) ns
Male:female (procedure based) 28:22 33:21
Male:female (patient based) 12:12 18:11
Mean age, years ns
Procedure based 61 65
Patient based 60.5 66
Older than 65 years old, n (%) ns
Procedure based 16 (32 %) 25 (46.8 %)
Patient based 7 (29 %) 15 (52 %)
Primary tumor origin, n (%)
Procedure based
Colorectal cancer 15 14 ns
Hepatocellular carcinoma 11 14
Neuroendocrine tumor 9 13




Colorectal cancer 5 7
Hepatocellular carcinoma 6 7
Neuroendocrine tumor 4 8
Breast cancer 4 2
Cholangiocarcinoma 3 1
Others 2 4
Prior TACE 6 9 ns
Activity planned GBq, median (range) ns
Procedure based 1.54 GBq (0.5–2.5) 1.45 GBq (0.5–2.4)
Patient based 1.5 (0.56–2.1) 1.4 (0.6–2.4)
Activity delivered GBq, median (range)
Procedure based 1.05 (0.2–2.29) 1.2 (0.3–2.4) 0.04
Patient based 1.0 (0.4–2.1) 1.4 (0.6–2.4) 0.005
Treatment approach, n (%) ns
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to prime the delivery set then suspend the 90Y resin mi-
crospheres. An aliquot of the 90Y resin microsphere sus-
pension was loaded into the A-line for deposition into
the hepatic artery and flushed through with 2 mL sterile
water (or G5W) followed by 2 mL non-ionic CM and fi-
nally 3–5 mL sterile water (or G5W). These steps were
repeated until the prescribed activity was delivered to
the patient or stasis. Any residual activity was calculated
according to a previously described method [23]. A re-
sidual activity less than or equal to 5 % was considered
as 100 % delivery of the calculated activity. Within 24 h
of SIRT, planar Bremsstrahlung scintigraphy (BS) of the
upper abdomen followed by a SPECT/CT scan was per-
formed in all patients [18].
Definition of early stasis and flow reduction
As mentioned above, an early stasis is defined as a lack
of an antegrade flow at angiography during infusion. A
significant flow reduction is defined as a reduction in
flow, verified by interventional radiologists as the con-
trast column clear within two to five heartbeats [24].
Statistical analysis
Variables of interest were calculated using descriptive
statistics. The chi-square test (χ2) was used to compare
different variables in the sterile water and glucose 5 %
water (G5W) groups. For the comparison of variables
with a normal distribution, a t test was used. Statistical
analysis was performed using a commercially available
software package (SPSS 20, IMB, Armonk, NY, USA).
Values of p < 0.05 were considered significant. The data
were analyzed not only according to the number of pro-
cedures but also as patient based.
Results
Patients and procedure
One hundred and four SIRT procedures were performed
on 78 patients (45 male, mean age: 63 years old, range:
31–87 years old) with either unresectable HCC or chol-
angiocarcinoma or chemorefractory liver-dominant
metastatic cancer (Table 1). Twenty-five patients under-
went sequential therapy as a lobar treatment (32 %),
some (n = 8) receiving their second procedure with
G5W (Table 1). Fifty-three patients underwent only one
procedure as lobar (in 42 patients (79.2 %)), whole-liver
(10 patients (18.9 %)), or segmental (1 patient (1.9 %))
SIRT (Table 1). Because of inhomogeneity of the data
between the patients with sequential treatments (e.g., de-
veloping stasis in one treated lobe or using glucose and
water for different lobes in the same patient), we ex-
cluded these patients from the patient-based analysis.
Before December 2013, 50 procedures were performed
with sterile water on 41 patients (mean age: 61 years),
and subsequently, 54 procedures were performed with
G5W on 37 patients (mean age: 65 years). There were no
significant differences identified between the treatment
groups for any baseline characteristics: either patient,
tumor type (prior treatment—all patients with metastases
had chemorefractory disease), or SIRT procedure. The
mean lung shunt was 3.2 % (0.7–15 %).
Flow reduction, stasis, and administered activity
Tables 2 and 3 summarize the results from our analyses.
Stasis or significant flow reduction occurred in 56 and
20 % of procedures as well as 58.3 and 6.9 % of patients
with sterile water and G5W, respectively (p < 0.0001). A
stasis alone occurred in 28 and 11 % of procedures as
well as 29.2 and 6.9 % of patients with sterile water and
G5W, respectively (p = 0.02 and 0.03, respectively).
The administration of the whole calculated activity
with air shot at the end of the procedure was possible in
11 of 50 (22 %) and 46 of 54 (85 %) procedures as well
as in 5 of 24 (20.8 %) and 28 of 29 (96.6 %) of patients
with sterile water and G5W, respectively (p < 0.0001).
According to all the procedures, because of flow reduc-
tion or stasis, a mean of 77.4 ± 24.3 % and 96.1 ± 11.0 %
of the calculated activity was administered in the sterile
Table 2 Post-treatment parameters according to number of
procedures with each application agent for SIRT
Sterile water Isotonic 5 %
glucose (G5W)
p value*
(n = 50) (n = 54)
Stasis or flow reduction, n (%) <0.0001
No 22 (44 %) 43 (80 %)
Yes 28 (56 %) 11 (20 %)
Stasis, n (%) 0.02
No 36 (72 %) 48 (89 %)
Yes 14 (28 %) 06 (11 %)
Mean activity delivered
(as a percentage of
planned activity)
77.4 ± 24.3 % 96.1 ± 11.0 % <0.001




100 % 22 (44 %) 47 (87 %)
90–95 % 04 (8 %) 01 (2 %)
80–89 % 03 (6 %) 01 (2 %)
50–79 % 15 (30 %) 5 (9 %)
<50 % 6 (12 %) 0 (0 %)
Mild-to-moderate abdominal
pain during application of
SIRT, n (%)
<0.0001
Yes 22 (44 %) 1 (1.8 %)
No 28 (56 %) 53 (98.2 %)
*Chi-square test
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water and G5W groups, respectively (p < 0.001). In the
patient-based analysis, it was 74.7 ± 25.9 % and 99.6 ±
1.9 % in the sterile water and G5W groups, respectively
(p < 0.001). A prior TACE did not have any effect on
early flow reduction or stasis (p = 0.46).
Safety
Over at least the 3-month follow-up post-procedure(s),
no patient developed gastroduodenal ulcer or
radioembolization-induced liver disease (REILD). Mild-
to-moderate upper abdominal pain occurred in 22 of 50
(44 %) and 1 of 54 (1.8 %) procedures as well as 9 of 24
(37.5 %) and 1 of 29 (3.4 %) with sterile water and G5W,
respectively (p < 0.0001 and 0.002, respectively).
Discussion
This retrospective review of patients from the same cen-
ter found that the incidence stasis during SIRT was sig-
nificantly reduced when using non-ionic CM and
isotonic glucose 5 % water (G5W) for the administration
of 90Y resin microspheres rather than sterile water. With
a lower incidence stasis, a higher percentage of the
planned activity for 90Y was administered using G5W as
the delivery medium (compared with sterile water). Fur-
thermore, significantly fewer patients reported mild-to-
moderate pain and discomfort during the procedure.
This analysis provides preliminary data to support our
hypothesis that the administration of 90Y resin micro-
spheres with an isotonic solution decreases the likelihood
of stasis (probably due to a reduction in vasospasm) dur-
ing SIRT. This finding is congruent with the delivery of
other intra-arterial therapies including glass microspheres
(which uses isotonic saline solution). None of the patients
in this case series experienced gastrointestinal events due
to the non-target delivery of SIRT, and so, our contention
that G5W may also reduce the non-target delivery of 90Y
resin microspheres due to reflux needs to be evaluated
further in a larger cohort of patients.
These are encouraging findings since stasis not only
prohibits the forward flow (and delivery of the entire
planned activity of 90Y) but may not improve, and so,
treatment with SIRT may need to be halted before com-
pletion of the prescribed activity. This is of concern par-
ticularly when less than 50 % of the planned activity of
90Y is delivered (as in 12 vs. 0 % of the sterile water and
G5W procedures, also in 16.7 and 0 % of the patients in
this study, respectively). Fortunately, stasis resulting in a
significant reduction in the administration of the
planned activity is a relatively rare event. In a study of
680 patients who received SIRT with 90Y resin micro-
spheres using sterile water, 1.1 ± 0.06 GBq (92 %) of the
1.2 ± 0.06 GBq of the mean (±SD) planned activity was
administered [25]. In a further study of 606 patients
(also using sterile water), a median 1.17 GBq (94 %) of
1.25 GBq of the planned activity was administered with
the first SIRT procedure and a median of 0.66 GBq
(92 %) of 0.72 GBq with the second SIRT procedure;
notably, in this second published series, the delivered ac-
tivity did not appear to be a function of the planned ac-
tivity (i.e., higher planned activities did not markedly
increase the risk of stasis or diminish the percentage
activity delivered).
Given the small volume of microspheres contained in
a vial, the majority of the microspheres are infused after
the first few milliliters of sterile water or G5W solution.
This is a relatively low treatment volume compared with
previous chemotherapy or loco-regional treatments
(such as TACE). In an in vivo pig model, clustering of
90Y resin microspheres was rarely observed and more
likely to be caused by intra-procedural arterial spasm ra-
ther than the inherent tendency of the microspheres to
aggregate [8]. This supposition is supported by in vivo
studies showing the injurious effects of sterile water on
the vascular endothelium leading to vasospasm [16, 17].
Unlike stasis, observed reductions in flow (character-
ized by diminished clearing of CM during SIRT) often
improves. It is important to consider whether the inci-
dence of stasis and reductions in the flow may also be a
function of the injection speed and the skill and
Table 3 Post-treatment parameters according to number of
patients with each application agent for SIRT
Sterile water Isotonic 5 %
glucose (G5W)
p value*
Stasis or flow reduction, n (%) <0.0001
No 10 (41.7 %) 27 (93.1 %)
Yes 14 (58.3 %) 02 (6.9 %)
Stasis, n (%) 0.03
No 17 (70.8 %) 27 (93.1 %)
Yes 7 (29.2 %) 02 (6.9 %)
Mean activity delivered
(as a percentage of
planned activity)
74.7 ± 25.9 % 99.6 ± 1.9 % <0.001




100 % 8 (33.4 %) 28 (96.6 %)
90–95 % 04 (16.7 %) 01 (3.4 %)
80–89 % 02 (8.3 %) 0 (0 %)
50–79 % 6 (25 %) 0 (0 %)
<50 % 4 (16.7 %) 0 (0 %)
Mild-to-moderate abdominal
pain during application
of SIRT, n (%)
0.002
Yes 9 (37.5 %) 1 (3.4 %)
No 15 (62.5 %) 28 (96.6 %)
*Chi-square test
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experience of the interventional radiologists (although,
in this study, we tried to minimize this factor by
using the same clinician and injection technique
throughout the study). The use of microcatheters also
permits the administration of 90Y resin microspheres
at low and consistent flow rates while at the same
time enabling adequate flow rates and particle sus-
pension [10]. Other factors which may impact on the
effective delivery of SIRT is the number of prior lines
of chemotherapy—since patients who have recently
received chemotherapy have vessels prone to dissec-
tion and spasm. In addition, diminished cardiac out-
put in elderly patients may result in slower than
expected hepatic arterial flow. Even though steps were
taken to verify the similarity of each of our compara-
tor groups in this analysis, further prospective evalu-
ation in larger cohorts of patients is needed to ratify
our findings.
Conclusions
In conclusion, using non-ionic contrast and isotonic glu-
cose 5 % (G5W) during the administration of 90Y resin
microspheres rather than sterile water appears to favor-
ably impact on the safety of SIRT, eliminate and/or
minimize flow reductions/stasis during administration,
and improve percentage activity delivered as well as the
ease of delivery of 90Y resin microspheres and improved
peri-procedural patient comfort.
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